Non-Interventional Post-Authorisation Safety Study (NI-PASS) as an effectiveness check of an additional Risk Minimisation Measure (aRMM) (Direct Healthcare Professional Communication [DHPC]) for Bendamustine First published 14/05/2020 Last updated 02/07/2024 EU PAS number:EUPAS34255 Study Finalised